Announcement of issuance by third-party allotment and completion of payment for the 14th stock acquisition rights. Total subscription amount is 1,400,000 yen, potential shares amount to 10,000,000 shares, and terms including the adjusted reference price and lock-up are specified.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4893","jir_company_name":"Noile-Immune Biotech Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4893-20261005-01.pdf","jir_short_summary":"Announcement of issuance by third-party allotment and completion of payment for the 14th stock acquisition rights. Total subscription amount is 1,400,000 yen, potential shares amount to 10,000,000 shares, and terms including the adjusted reference price and lock-up are specified.","jir_summary":"### Notification of Issuance of Stock Acquisition Rights and Completion of Payment\nNoile-Immune Biotech Inc. has announced that payment for the 14th series of stock acquisition rights issued by third-party allotment has been completed. As a summary of the offering, the number of stock acquisition rights issued is 100,000 units, the issue price is 14 yen per unit (total 1,400,000 yen), and the number of potential shares is 10,000,000 shares. The adjusted reference price is calculated based on 95% of the Tokyo Stock Exchange closing price, and the lower exercise price is 81 yen. The amount of funds to be raised is estimated at a total of 1,349,400,000 yen, and the allottee is Okasan Securities Co., Ltd. Lock-up and other conditions are also included in the agreement.\n\n### Allotment, Exercise Period and Conditions\nThese stock acquisition rights have an exercise period set from the banking business day following the allotment date until October 5, 2028, and the third-party allotment agreement includes constraints such as exercise restriction periods, lock-up, and transfer approval. The actual amount of funds raised may vary depending on the level of exercise prices, and the final fundraising amount will increase or decrease depending on whether the rights are exercised.","jir_financial_highlights":"Amount of funds to be raised: 1,349,400,000 yen (note) (Note attached)\nNumber of stock acquisition rights issued: 100,000 units (Unknown)\nIssue price: 14 yen\/unit (total 1,400,000 yen) (Unknown)","jir_category":"","jir_hashtags":"#NoileImmuneBiotech, #CapitalPolicy_includingScheduleAndConditions, #IssuanceOfStockAcquisitionRights","jir_key_figures":"Number of stock acquisition rights issued: 100,000 units\nIssue price: 14 yen\/unit (total 1,400,000 yen)\nAmount of funds to be raised: 1,349,400,000 yen\nPotential shares: 10,000,000 shares\nLower exercise price: 81 yen\nAllottee: Okasan Securities Co., Ltd.\nExercise period: From the banking business day following the issuance date until October 5, 2028","jir_meta_title":"Noile-Immune Biotech Inc. - Notice of Completion of Payment for Stock Acquisition Rights Issuance | October 2026","jir_meta_description":"Noile-Immune Biotech Inc. has announced completion of payment for the 14th stock acquisition rights by third-party allotment. Total issue amount 1,400,000 yen, potential shares 10,000,000 shares, including adjusted reference price conditions and lock-up provisions.","jir_og_title":"Noile-Immune Biotech Inc. - Notice of Completion of Payment for Stock Acquisition Rights Issuance | October 2026","jir_og_description":"Announcement of completion of payment for the issuance of stock acquisition rights. Number issued 100,000 units, total 1,400,000 yen, potential shares 10,000,000 shares, including conditions such as lock-up.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59659,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-127551","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n